Controlled-Release Carbidopa/Levodopa in the Treatment of Parkinsonism
- 1 June 1984
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 7 (2) , 135-140
- https://doi.org/10.1097/00002826-198406000-00003
Abstract
Controlled release carbidopa/levodopa (CSR-1) was compared to standard carbidopa/levodopa in a double-blind, crossover study of 20 Parkinson's disease patients. The most consistent finding in a variety of clinical measurements was the superiority of standard carbidopa/levodopa to CSR-1. Increased dosages of CSR-1 resulted in reduced Parkinson symptoms, suggesting that a more potent controlled-release formulation might prove to be more efficacious than CSR-1.Keywords
This publication has 0 references indexed in Scilit: